Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
J Clin Neurosci ; 89: 389-396, 2021 Jul.
Article in English | MEDLINE | ID: mdl-34088580

ABSTRACT

BACKGROUND: The decision to resume antithrombotic therapy after surgical evacuation of chronic subdural hematoma (CSDH) requires judicious weighing of the risk of bleeding against that of thromboembolism. This study aimed to investigate the impact of time to resumption of antithrombotic therapy on outcomes of patients after CSDH drainage. METHODS: Data were obtained retrospectively from three tertiary hospitals in Singapore from 2010 to 2017. Outcome measures analyzed were CSDH recurrence and any thromboembolic events. Logistic and Cox regression tests were used to identify associations between time to resumption and outcomes. RESULTS: A total of 621 patients underwent 761 CSDH surgeries. Preoperative antithrombotic therapy was used in 139 patients. 110 (79.1%) were on antiplatelets and 35 (25.2%) were on anticoagulants, with six patients (4.3%) being on both antiplatelet and anticoagulant therapy. Antithrombotic therapy was resumed in 84 patients (60.4%) after the surgery. Median time to resumption was 71 days (IQR 29 - 201). Recurrence requiring reoperation occurred in 15 patients (10.8%), of which 12 had recurrence before and three after resumption. Median time to recurrence was 35 days (IQR 27 - 47, range 4 - 82 days). Recurrence rates were similar between patients that were restarted on antithrombotic therapy before and after 14, 21, 28, 42, 56, 70 and 84 days, respectively. Thromboembolic events occurred in 12 patients (8.6%), of which five had the event prior to restarting antithrombosis. CONCLUSIONS: Time to antithrombotic resumption did not significantly affect CSDH recurrence. Early resumption of antithrombotic therapy can be safe for patients with a high thromboembolic risk.


Subject(s)
Anticoagulants/administration & dosage , Drainage/methods , Fibrinolytic Agents/administration & dosage , Hematoma, Subdural, Chronic/surgery , Neurosurgical Procedures/methods , Postoperative Complications/etiology , Thromboembolism/epidemiology , Adult , Aged , Anticoagulants/therapeutic use , Cohort Studies , Drainage/adverse effects , Fibrinolytic Agents/therapeutic use , Hematoma, Subdural, Chronic/drug therapy , Humans , Middle Aged , Neurosurgical Procedures/adverse effects , Postoperative Complications/epidemiology , Reoperation/statistics & numerical data , Thromboembolism/drug therapy
2.
Br J Neurosurg ; 35(6): 719-724, 2021 Dec.
Article in English | MEDLINE | ID: mdl-32530308

ABSTRACT

AIM: This article aims to inform and share the experience of a Singaporean tertiary level neurosurgical unit in an academic medical centre during the COVID-19 outbreak. METHOD: This is a descriptive study of our segregation team model which is designed with the aim of optimizing manpower and ensuring the safety and welfare of the neurosurgical unit, while maintaining and prioritizing excellent patient care. RESULT: We describe our method of team segregation, rostering, and outline some principles that we adhere to in its design. We also summarise the restructuring of our inpatient and outpatient service, including the operating theatre and protocols for specific procedures, intensive care and general wards, as well as clinic services and multidisciplinary meetings. CONCLUSION: We end with a commentary on residency training and anticipated challenges. Given the likely protracted course of the pandemic, it is key to account for sustainability of such measures and the conservation of resource via the reduction of pateint volume, upkeep of staff emotional and physical health and harnessing technologies such as telemedicine.


Subject(s)
COVID-19 , Academic Medical Centers , Disease Outbreaks , Humans , SARS-CoV-2 , Singapore/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...